RAMP For Anthrax Available Before Cardiac Markers – Response Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Response Biomedical Corp. will initially target government agencies and public health sites with its Rapid Analyte Measurement Platform (RAMP) anthrax test before fully commercializing the device
You may also be interested in...
Response Biomedical Cuts Staff By Two-Thirds, Cites Delayed RAMP 510(k)
Response Biomedical will cut its 36-employee workforce by roughly two-thirds and file for bankruptcy protection to sustain operations over the next several months as it continues to pursue FDA clearance of its RAMP diagnostic system.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.